Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 17/20 | 0.59 |
| ▸ | CTSL | P07711 | 16/20 | 0.59 |
| ▸ | CTSS | P25774 | 15/20 | 0.59 |
| ▸ | CTSK | P43235 | 5/20 | 0.59 |
| ▸ | CTSD | P07339 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576260 | 0.91 | CTSB (0.72) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4577119 | 0.89 | CTSB (0.60) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576702 | 0.87 | CTSB (0.68) | CTSBCTSLCTSSCTSKCTSD | |
| Maleic Acid SCHEMBL5565097 | 0.86 | CTSB (0.65) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576214 | 0.85 | CTSB (0.55) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4577313 | 0.84 | CTSL (0.54) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576796 | 0.84 | CTSB (0.82) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL6185943 | 0.83 | CTSB (0.68) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576517 | 0.83 | CTSB (0.54) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576241 | 0.82 | CTSB (0.65) | CTSBCTSLCTSSCTSKCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254124-B1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2008-07-30 | — | — | EP | claimed |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | ZIMMERMANN JOHANN | 2006-12-14 | — | — | US | claimed |
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | MISSBACH MARTIN (CH) | 2003-10-30 | — | — | US | claimed |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2001-08-23 | — | — | US | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1254124-B1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-20070191392-A1 | DIPEPTIDE NITRILE CATHESPIN K INHIBITORS | NORVARTIS AG (CH) | 2007-08-16 | — | — | US | disclosed |
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | MISSBACH MARTIN | 2007-06-14 | — | — | US | disclosed |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | ZIMMERMANN JOHANN | 2006-12-14 | — | — | US | disclosed |
| US-20050267129-A1 | Dipeptide nitrile cathepsin K inhibitors | NORVARTIS AG (CH) | 2005-12-01 | — | — | US | disclosed |
| US-6642239-B2 | Compounds such as N-(1-(cyanomethylcarbamoyl)cyclohexyl)-4-(piperazin-1-yl)-benzamide | NOVARTIS AG (CH) | 2003-11-04 | — | — | US | disclosed |
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | MISSBACH MARTIN (CH) | 2003-10-30 | — | — | US | disclosed |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2001-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | CTSK, CTSB, CTSZ | CTSB 2/4885CTSL 10/4885CTSS 8/4885 |
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | CTSB 8/4885CTSL 4/4885CTSS 3/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | CTSB 2/4885CTSL 13/4885CTSS 3/4885 |
| US-20050267129-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSL, CTSV | CTSB 7/4885CTSL 2/4885CTSS 4/4885 |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | CTSB 8/4885CTSL 4/4885CTSS 3/4885 |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | CTSK, CTSB, CTSZ | CTSB 2/4885CTSL 11/4885CTSS 7/4885 |
| US-20070191392-A1 | DIPEPTIDE NITRILE CATHESPIN K INHIBITORS | CTSL, CTSK, CTSC | CTSB 14/4885CTSL 1/4885CTSS 6/4885 |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | BST2, BSG, CD44 | CTSB 445/4885CTSL 400/4885CTSS 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.